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Abstract
Influential American medical organizations and publications have published guidelines for the treatment of acute migraine
headaches that omit antiemetics, usually suggesting triptans as the first line of treatment. A review of the few comparative
studies directly contrasting clinical outcomes of triptans and antiemetics in the treatment of acute migraines suggest that
both treatment options are relatively equal in efficaciousness. The added burden of triptan usage, including an added risk
of adverse effects and a high cost per dose, would seem to warrant an antiemetic-first approach to migraine treatment,
as recommended by several international health communities. Possible reasons for the prominent omission of antiemetics
from leading publications may include medical parochialism and pharmaceutical funding of medical research.
Introduction
In January 2002, the New England Journal of Medicine published a
paper entitled “Migraine-Current Understanding and Treatment,”
written by several leading neurologists. The paper reviewed
all the current treatment options for migraine headaches, and
strongly emphasized triptans, a relatively new class of drugs
developed by drug companies specifically to address migraines
(Goadsby et. al., 2002). One of the most notable aspects of the
paper was that it completely omitted the drug class antiemetics,
which is increasingly used nationally and internationally, mostly
among emergency medicine practitioners, to treat acute migraine
headaches (Seguil & Lax, 2014). One factor for this omission may
have been the varied perspectives which can often develop between members of different specialties of medicine, with neurologists recommending one therapy and emergency medicine
doctors recommending another (Newman, 2009). Nevertheless,
it is likely that the authors were aware of the therapeutic history
of antiemetics for migraine headaches, and they chose to omit
it. In fact, the papers recommendations are completely consistent with the guidelines published by the American Academy of
Neurology (n.d.).The purpose of this review is to assess whether
these influential omissions are in fact warranted by clinical observation and meta-analysis, or if antiemetics should be considered
an efficacious treatment for acute migraines with the right clinical
indications. Possible biases that could have caused conscious or
subconscious influences on the recommendations of different
groups will also be analyzed as a method of understandings them.

Methods
In order to assess antiemetics as an efficacious treatment option
for acute migraines, a meta-analysis of the published literature
was undertaken. Comparative studies between the effectiveness
of triptans and antiemetics is the main focus. In assessing clinical
value, both primary effectiveness and secondary side-effect prevalence were surveyed to accurately portray an overall picture of
patient outcomes. Clinical trials were obtained using the National
Institute of Health’s PubMed search engine, and only studies published in reputable academic journals were included.

Migraine Headaches
A migraine headache is defined as a headache that usually affects

one specific area or side of the head and is frequently accompanied by nausea, sensory sensitivity, and possible neuralgia (Ferrari,
2013). Headaches accompanied by neuralgia have been recorded
since ancient times, as far back as the ancient Egyptians (Miller,
et. al. 2005). The difference between a normal headache and a
migraine is often one of degree and thus cannot always be definitively assessed; however, chronicity can be an important indicator
of migraines. The first modern treatment for migraines was ergotamine (Woakes, 1868), which was originally hypothesized to
slow the stimulation of sympathetic nervous pathways (although
its mechanism is now contested). The pathogenesis of migraines
was illuminated in the 1940s, when serotonin was isolated as a
potent cause of migraines (Wolff, 1948).This discovery led to the
serotonin-inhibiting class of migraine treatments, starting with
methylsergide, which was first used in the middle of the 20th
century (Sicuteri, 1959).
This paper focuses on two modern therapies for migraine headaches: triptans, of which the prototype drug is sumatriptan, discovered in 1988, and antiemetics, which are primarily anti-nausea medications, including domperidone, metoclopramide, and
prochlorperazine. These drugs are typically given together with
an analgesic, usually aspirin. Other commonly used pain-relieving
drugs, such as NSAIDs, caffeine, and codeine should be noted, but
are not of specific interest to this discussion.

Triptans
Triptans were first used in the treatment of migraines during the
1980’s, when interest surged in examining the role of serotonin
(5-HT) in the pathogenesis and pathophysiology of migraines
(Bateman, 2000). Triptans are a class of drugs that affect serotonin receptors, commonly called 5-HT receptors, of which there
are many subtypes. Triptans are 5-HT agonists, binding with high
affinity to many 5-HT subtypes that cause potent vasoconstriction of many intracranial blood vessels. They also affect various
neurotransmitters and chemical mediators, but no specific effect has been conclusively tied to theiranti-neuralgic properties.
Because of a variety of concerns regarding the effectiveness of
the original triptans, such as variable bioavailability, variable absorption, and significant adverse effects, new classes of triptans
have been continuously developed by drug companies. Some of
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the most recent triptans typically prescribed for migraine headaches include almotriptan, frovatriptan, and avitriptan (Loder,
2010). Although the mechanism of the therapy remains unclear, it
is generally recognized in the United States as a first-line therapy
for patients unresponsive to analgesics. Triptans provide relief of
symptoms within the first 10-60 minutes of use, depending on
route of entry (Loder).

Antiemetics
Antiemetics are drugs that relieve symptoms of vomiting and
nausea. They are usually used to treat motion sickness and to
relieve the side effects of nausea-causing therapies. The use of
antiemetics as a direct therapy for migraine headaches was a
serendipitous discovery. Originally, antiemetics were used to
allow sufferers of migraines to ingest drugs given to relieve the
headaches. However, physicians soon began to notice that the
symptoms of the migraine headaches were relieved before the
primary therapy could be given. Thus antiemetics soon became
the drug of choice, especially among emergency medicine practitioners, to treat analgesic-resistant headaches (Newman, 2009).

Comparative Studies
Unfortunately, and for possible reasons that will be addressed
further, there are very few studies that directly compare the
efficaciousness of triptans and antiemetics in the treatment of
migraine headaches (Gupta et. al., 2002). However, a number of
studies have been completed globally that directly contrast these
two treatment options.
The first comparative study was published in 1995, comparing
oral sumatriptan (a triptan) with lysine acetylsalicylate plus metopramide (an aspirin plus an antiemetic) in their effectiveness
in treating migraines (Tfelt-Hanson et. al., 1995). This study was
conducted between October 26, 1993 and July 18, 1994 at over
68 medical centers in Belgium, Denmark, the Netherlands, and
France, and included only patients with significant histories of
migraine headaches. It was a randomized, double-blind study,
which included follow-up for up to as eight weeks, as needed.
Four hundred twenty-one patients participated in the study. The
study showed that in numerous benchmarks for effectiveness,
the two treatment options were virtually identical, including improvement in immediate headache severity, control of adverse
effects, headache recurrence, and patient satisfaction.The authors
concluded that “there is no difference in primary or secondary
efficacy between LAS+MTC and oral sumatriptan…because of
its high price physicians should consider whether the routine use
of sumatriptan as the initial treatment of a migraine attack really
is preferable to the use of cheaper drugs such as analgesics combined with an antiemetic.” Indeed, in Europe and in many other
countries, these recommendations are generally considered best
practice (Newman, 2009).

8

A subsequent study was performed in three medical centers in
France, with a total of 666 participating patients (Geraud et. al.,
2002). It was a multicenter, double-blind, randomized study, and
follow up was performed until fifteen days after the last migraine
attack took place. Each patient was given one of the following: acetylsalicylic acid plus metoclopramide, zolmitriptan, or a
placebo. The patients were then requested to keep an hourly
diary to record headache relief, overall pain relief, nausea levels, any adverse effects, and overall satisfaction with the therapy. The study results seemed to be inconclusive initially, as the
authors wrote: “Both treatments reduced migraine-associated
nausea, vomiting, phonophobia and photophobia. There were no
important inter-group differences with respect to the onset of
meaningful migraine relief, the frequency of headache recurrence,
the usage or efficacy of a second dose of medication or the use
of escape medicine.” However, the authors preceded to perform
what they called a “post hoc analysis,” in which they found certain benefits to triptan use, including a greater overall patient
satisfaction, overall pain-free reporting (as opposed to headache
pain), a greater efficacy in patients with “migraine associated with
menses,” and the fact that triptan use was “unaffected by age,
weight, or gender.” They thus concluded that “Although evaluation using the primary end point in this study was inconclusive,
other end points such as freedom from pain, now identified as
more clinically relevant end points, showed zolmitriptan 2.5 mg
to be significantly better that the standard analgesic-anti-emetic
combination of acetylsalicylic acid and metoclopramide.” In summary, this study found slight benefits to triptan use, although it is
important to note that for all the primary end points designated
before the study was completed, the therapies were identical.
Only after the data was collected did the authors find certain
benchmarks that could be identified as benefits to triptan use.
This is generally considered a far less objective method of gathering data, as it allows the investigator considerable latitude in
actively picking specific data sets. In what may be an important
note, the study concludes with an acknowledgement that “this
study was supported by AstraZeneca Pharmaceuticals.”
A third study, performed in New York City, compared aggressive
metoclopramide treatment, consisting of four infusions within
the first two hours, to subcutaneous sumatriptan treatment of
migraine headaches (Friedman et. al., 2005). Two hundred two
patients participated in the trial. Patients were not followed after
the initial twenty-four-hour period, which can be considered a
weakness in their overall assessment of the therapies; in fact, only
37 of the patients completed the twenty four-hour follow-up
protocol. In addition, the patient population studied was almost
completely comprised of individuals of Latino origin, making extrapolations to general populations uncertain.Another concern is
that the study excluded those suffering chronic migraines, which
may be a population which reacts differently to specific therapies.
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The study concluded that there were no significant differences
between the two therapy options in reaching the primary end
points of the study, including headache relief, nausea relief, and
overall well-being. However, in their own post hoc analysis, the
authors find certain benefits to metoclopramide use, including
twenty-four-hour symptom relief.
A fourth comparative evaluation was performed in Iran at the
Isfahan University of Medical Sciences, comparing metoclopramide to sumatriptan for migraine headache treatment (Talabi
et. al., 2013). This study was performed on emergency room
patients. One hundred twenty-one subjects were included in
this randomized, double-blind study. Several introductory notes
should be mentioned about this study. First, the command of the
English language displayed by the authors is competent overall
but nevertheless displays signs of possible grammatical and idiomatic peculiarities which may or may not result in important,
altered connotations (for example, the authors wrote that their
study included a “controlled study design and patient blindness”).
Second, the study noted that “it is surprising that no subjects in
both groups complained of adverse effects.” This is a significant
deviation from other comparable studies, which may be a cause
for concern. The authors attempt to explain this discrepancy as
“a result of slow metoclopramide injection and the way the question about these effects were phrased.” It also may be a reflection
of cultural differences in the way side effects are described, or
how often, or upon what level of acuteness, they are remarked
upon. The patients were all observed during the initial hour after
they were treated. The results of this trial were that metoclopramide was superior to sumatriptan in headache relief (Talabi).
In summary, there are very few studies that directly compare
triptans to antiemetics for acute migraine headache relief. The
few that have been performed suggest that the therapies are relatively similar in effectivity for all primary end points.

Triptans vs Antiemetics: Other Differences
The fact that triptans and antiemetics have been shown to have
similar outcomes in treating migraines does not necessarily mean
that they are equally sound treatment options. In fact, there are
several reasons why triptans may be a less advisable treatment
option. The first is adverse effects. Triptans are known to cause
several negative effects in patients. The most common set of adverse side effects, affecting almost half of all triptan users, is often
referred to as triptan sensations, and includes upper chest pressure or pain and epithelial flushing. Rare cardiovascular events
have also been reported and triptans are thus contraindicated in
those with possible cardiac disease. This stands in contrast to antiemetics, and specifically to metoclopramide, which have minimal
reported adverse effects. The second shortcoming of triptans is
their often high price, with the average cost of a single triptan pill

typically exceeding ten dollars, while a single dose of antiemetics
can cost less than ten cents (Adelman et. al., 2004). The benefits
of antiemetics are thus both in terms of adverse effects, which
are minimal, and cost, as they are extremely cheap therapy to
provide to patients. Therefore, if antiemetics can be shown to
be comparably effective to triptans in specific clinical settings,
which seems to be the case, they can plausibly be considered
a superior therapy overall under those conditions. Thus it remains puzzling how the 2002 review article in the New England
Journal of Medicine completely omitted antiemetics in its review
of migraine relief protocols, and why it is omitted from the recommendations of the American Academy of Neurology on the
treatment of migraines.

Medical Parochialism
Parochialism in research has been a phenomenon long noted and
lamented by meta-researchers (March, 2005). It is often based
on nationality, with different countries’ research communities
favoring different approaches. These differences can have cultural,
ideological, or experiential origins. Parochialism can also be of
disciplinary origin. In the medical field, this has often been the
case; for example, medical doctors and nurse practitioners often
find themselves at odds over a variety of disciplinary differences
(Phillips et. al., 2002). In the specific case of the triptan vs. antiemetic debate, the difference in recommendations may have arisen from the different perspectives that neurologists and emergency medicine doctors have of migraine sufferers. Emergency
medicine practitioners generally see patients who are in the midst
of acute migraine attacks. Therefore, their perspective is geared
toward therapies that are most efficacious at immediate migraine
relief, and this may factor into their preference of antiemetics to
triptans (Friedman et. al., 2014). Neurologists, on the other hand,
see mostly patients who are chronic migraine sufferers, and may
therefore strongly favor treatments that provide longer-lasting
relief. Nevertheless, it must be emphasized that the review in
the New England Journal of Medicine was a complete review of
both acute and chronic migraine treatments, and thus explicitly
included the medical protocols in which emergency medicine
practitioners are most experienced. It is therefore quite possible
that parochialism is at fault for the varying guidelines proposed to
treat migraines, where one field’s inherent biases led it to ignore
or be unfamiliar with the practices of other fields. (It should be
noted, however, that the 2005 study that found that antiemetics
were comparable to triptans was authored by emergency room
doctors and was published in the journal Neurology.)

Pharmaceutical Funding
Surveying the comparative studies of triptans and antiemetics
brings to the fore the often uncomfortable question of relationships between for-profit companies and medical institutions and
research facilities (Smith, 2003). Although many regulations have
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been passed over the last few decades, which have helped prevent the more egregious practices of pharmaceutical companies,
many interactions remain that might possibly compromise clinical
objectivity (Brody, 2005). It is certain that drug companies would
favor the use of expensive, patented triptans over the cheap antiemetic drugs, and it is thus distressing that a drug company was
the primary funder of the single comparative study that found, in
post hoc data examination, that triptans were a superior treatment option. The other studies were free of any reportable conflict of interest, and came to different conclusions. In addition, the
review article from the New England Journal of Medicine, which
strongly focused on and recommended triptan use, closes with
a fine-print disclosure that all the authors have been recipients
of grant funding or have acted as consultants for many different
drug companies, including all those that currently manufacture
triptan medications (Newman, 2009). This fact may explain why
the authors, consciously or not, were especially focused on triptan therapy. Of course, this does not mean to slander the authors
in any way or to impugn their professional reputation, but rather
to bring into focus the problems associated with industry funding
of scientific enterprises. Certainly, the fact that such funding is
indispensable to many research projects cannot be ignored, but
perhaps other remedies, such as the mandatory authorship of
one author without reportable conflicts of interest, can be advanced to protect the integrity of these studies.
Another important question regarding pharmaceutical company
funding of medical research is the types of studies performed.
For example, if a pharmaceutical company deems a therapy to
be dangerous toward its bottom line, it may simply withdraw all
funding for studies pursuing that therapy, leaving little incentive
for researchers to pursue it. This may explain why so few studies
have actually been performed comparing triptans directly with
almost any other therapy, including antiemetics, and instead most
research in the field consists of large studies, including thousands
of patients (Ferrari et. al., 2002), which look solely at the benefits
of triptans.
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